Literature DB >> 23882961

Characterization of wound infections among patients injured during the 2011 Libyan conflict.

A A Dau1, S Tloba, M A Daw.   

Abstract

Few studies have analysed the bacterial pathogenesis of infections associated with war-wound in the Eastern Mediterranean region. We analysed surgical wound infections of 1200 patients injured during the Libyan conflict in 2011 and admitted to the emergency services at Tripoli medical centre. Culture swabs or surgical wound debridement samples were collected and cultures were identified and tested for antimicrobial resistance. Of the 1200 patients studied, 498 (42%) were infected with at least 1 pathogen and 57 with >2 pathogens. The most common species were Acinetobacter spp. (isolated from 144 patients), coagulase-negative staphylococci (122), Escherichia coli (107), Pseudomnonas aeruginosa (92) and Klebsiella spp. (86). A high level of resistance to the antibiotics tested was found, especially among Acinetobacter spp. Multi-drug-resistant Gram-negative bacilli were an important complicating factor in wound infections associated with war injuries among injured patients in Libya. Effective policies are needed to control and treat such infections particularly in trauma and emergency services.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23882961

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  12 in total

1.  Epidemiology and antimicrobial susceptibilities of wound isolates of obligate anaerobes from combat casualties.

Authors:  Brian K White; Katrin Mende; Amy C Weintrob; Miriam L Beckius; Wendy C Zera; Dan Lu; William Bradley; David R Tribble; Elizabeth R Schnaubelt; Clinton K Murray
Journal:  Diagn Microbiol Infect Dis       Date:  2015-10-23       Impact factor: 2.803

Review 2.  Hepatitis C virus in Arab world: a state of concern.

Authors:  Mohamed A Daw; Aghnaya A Dau
Journal:  ScientificWorldJournal       Date:  2012-05-02

3.  Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission.

Authors:  Mohamed A Daw; Abdallah El-Bouzedi; Aghnaya A Dau
Journal:  BMC Res Notes       Date:  2015-08-21

4.  Seroprevalence of HBV, HCV & HIV co-infection and risk factors analysis in Tripoli-Libya.

Authors:  Mohamed A Daw; Amira Shabash; Abdallah El-Bouzedi; Aghnya A Dau
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

5.  Infection with high proportion of multidrug-resistant bacteria in conflict-related injuries is associated with poor outcomes and excess resource consumption: a cohort study of Syrian patients treated in Jordan.

Authors:  Andreas Älgå; Sidney Wong; Muhammad Shoaib; Kalle Lundgren; Christian G Giske; Johan von Schreeb; Jonas Malmstedt
Journal:  BMC Infect Dis       Date:  2018-05-22       Impact factor: 3.090

6.  Trends and patterns of deaths, injuries and intentional disabilities within the Libyan armed conflict: 2012-2017.

Authors:  Mohamed A Daw; Abdallah H El-Bouzedi; Aghnyia A Dau
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

7.  Therapeutic effect of ethylenediaminetetraacetic acid irrigation solution against wound infection with drug-resistant bacteria in a rat model: an animal study.

Authors:  Z Deng; F Liu; C Li
Journal:  Bone Joint Res       Date:  2019-06-05       Impact factor: 5.853

8.  Antimicrobial resistance in Africa: a systematic review.

Authors:  Birkneh Tilahun Tadesse; Elizabeth A Ashley; Stefano Ongarello; Joshua Havumaki; Miranga Wijegoonewardena; Iveth J González; Sabine Dittrich
Journal:  BMC Infect Dis       Date:  2017-09-11       Impact factor: 3.667

9.  Libyan healthcare system during the armed conflict: Challenges and restoration.

Authors:  Mohamed A Daw
Journal:  Afr J Emerg Med       Date:  2017-05-09

10.  The study of formulated Zoush ointment against wound infection and gene expression of virulence factors Pseudomonas aeruginosa.

Authors:  Maryam Meskini; Davoud Esmaeili
Journal:  BMC Complement Altern Med       Date:  2018-06-15       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.